This study indicates that blood REST protein levels are a novel, psychologically modifiable candidate biomarker of cognitive decline and AD.28 Peripherally circulating REST levels declined with increasing clinical severity, resulting in AD patients showing the lowest levels. This evidence concerns the gene REST and Alzheimer disease.